Комитетът по лекарствените продукти за хуманна употреба (CHMP) решава, че ползите от
The Committee for Medicinal Products for Human Use (CHMP) decided that Viraferon’ s benefits are greater than its risks for the treatment of chronic hepatitis B and C.